TGTX TG THERAPEUTICS, INC.

Nasdaq tgtherapeutics.com


$ 33.51 $ -2.72 (-7.49 %)    

Monday, 03-Nov-2025 12:32:42 EST
QQQ $ 632.53 $ -2.75 (-0.43 %)
DIA $ 473.78 $ -2.44 (-0.51 %)
SPY $ 683.28 $ -2.36 (-0.34 %)
TLT $ 89.57 $ -0.08 (-0.09 %)
GLD $ 368.57 $ -0.22 (-0.06 %)
$ 34.78
$ 36.31
$ 33.48 x 11
$ 33.53 x 7
$ 31.07 - $ 36.48
$ 22.92 - $ 46.48
3,259,737
na
5.52B
$ 1.76
$ 91.28
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-03-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 05-10-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-tg-therapeutics-raises-price-target-to-49

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $46...

 top-stocks-with-earnings-this-week-joby-ionq-amd-and-more

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

 tg-therapeutics-raises-fy2025-sales-guidance-from-585000m-to-600000m-vs-588045m-est

TG Therapeutics (NASDAQ:TGTX) raises FY2025 sales outlook from $585.000 million to $600.000 million vs $588.045 million estimate.

 tg-therapeutics-q3-eps-243-beats-022-estimate-sales-161709m-beat-152169m-estimate

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $0.22...

 small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

 ihc-wainwright--co-assumes-tg-therapeutics-at-buy-announces-price-target-of-60

HC Wainwright & Co. analyst Emily Bodnar assumes TG Therapeutics (NASDAQ:TGTX) with a Buy rating and announces Price Tar...

 tg-therapeutics-reports-near-zero-relapse-rate-after-6-years-of-briumvi-treatment-in-multiple-sclerosis-with-no-new-safety-signals

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring e...

 b-riley-securities-maintains-buy-on-tg-therapeutics-raises-price-target-to-55

B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fr...

 tg-therapeutics-ceo-voices-strong-conviction-in-briumvi-with-new-100-million-buyback

TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing co...

 tg-therapeutics-files-for-mixed-shelf-offering-size-not-disclosed

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION